Another study involved MEDI8968, a human IgG2 monoclonal antibody against IL-1R1, able to bind both IL-1α and IL-1b, and injected intravenously (600mg) and subcutaneously (300 mg), did not show any beneficial effects in COPD patients (GOLD stage II-IV) during exacerbated stages (clinical trial: NCT01448850) [74]. The gene discussed is IL1R1; the disease is chronic obstructive pulmonary disease.